Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) Completed Phase 3 Trials for Flu caused by Influenza / Influenza Vaccines Prevention

IndicationsStatusPurposePhase
CompletedPrevention3
clinicaltrials.gov IdentifierTitleDrugs
NCT00383123Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children
NCT02242643Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age
NCT00764790Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
NCT01773928Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
NCT01389479Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults
NCT00395174Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults
NCT00539864Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV
NCT00885105Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age
NCT00959049A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
NCT01218646Study of Quadrivalent Influenza Vaccine Among Adults
NCT01240746Study of Quadrivalent Influenza Vaccine Among Children
NCT01712984Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years